Abstract
Inhibition of plasma kallikrein (pKal) activity is a validated mechanism for prevention of hereditary angioedema (HAE) attacks. High potency and long duration of action are key drivers of prophylactic efficacy of pKal inhibitors. STAR-0215 is a novel, potent and selective long-acting monoclonal antibody plasma kallikrein pKal inhibitor in clinical development. In monkeys dosed subcutaneously, STAR-0215 inhibits pKal activity rapidly and durably. We investigated STAR-0215 structure and binding to pKal and its inhibitory mechanism of action by utilizing Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS) and Cryogenic Electron Microscopy (Cryo-EM).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
